More important, we established a genetically engineered mouse model (GEMM) to conditionally interrupt Klf5 acetylation, providing a unique animal model to address the role of Ac-KLF5 in the progression of PTEN-deficient prostate cancer (24). The gene discussed is KLF5; the disease is prostate carcinoma.